肠道菌群-PPARs轴在炎症性肠病中的作用

doi:10.20223/j.cnki.1000-8535.2024.11.002

摘要/Abstract

摘要： 炎症性肠病（IBD）作为一种慢性、易复发的炎症性疾病,被世界卫生组织归类为现代医疗领域的难治性疾病之一。其确切发病机制尚不清晰,目前主要认为与肠菌失衡触发宿主过度的肠黏膜免疫反应,进而在遗传易感性的个体中引发肠黏膜的损伤有关。目前,尚无特效的靶点能治愈IBD。过氧化物酶体增殖物激活受体（PPARs）作为核受体超家族的一员,在机体的生长发育、炎症调控以及代谢过程中扮演着重要角色,且被视为治疗包括IBD在内的多种疾病的重要潜在靶点,并被认为与肠道菌群关系密切。文章旨在探讨PPARs与肠道菌群的关系在IBD中的作用,从而挖掘IBD新的潜在诊疗靶点,开发新的治疗策略,为临床上IBD的诊断和治疗提供新的思路和方法。

关键词: 肠道菌群, 炎症性肠病, PPARs¹

Abstract: Inflammatory bowel disease（IBD）,characterized as a chronic and recurrent inflammatory condition,is classified by the World Health Organization as one of the intractable diseases in modern medicine．The precise pathogenesis of IBD remains unclear,but current research widely believes that it is closely related to dysbiosis of the gut microbiota．Imbalance in the gut flora triggers an excessive immune response in the host’s intestinal mucosa,leading to mucosal damage in genetically susceptible individuals．To date,no specific targets have been identified that can cure IBD．Peroxisome proliferator-activated receptors（PPARs）,as members of the nuclear receptor superfamily,play significant roles in growth and development,inflammation regulation,and metabolic processes．They are regarded as potential effective targets for treating various diseases,including IBD,and are closely related to the gut microbiota．This review aims to discuss the progress in understanding the role of the relationship between PPARs and gut microbiota in IBD,so as to find new potential targets for the diagnosis and treatment of IBD,develop new treatment strategies,provide new ideas and methods for the diagnosis and treatment of IBD in clinical practice．

Key words: gut microbiota, inflammatory bowel disease, PPARs

李建洪, 徐婧, 徐豪明, 黄琛, 聂玉强, 周有连. 肠道菌群-PPARs轴在炎症性肠病中的作用[J]. 广州医药, 2024, 55(11): 1246-1254.

LI Jianhong, XU Jing, XU Haoming, HUANG Chen, NIE Yuqiang, ZHOU Youlian. The role of PPARs- gut microbiota axis in inflammatory bowel disease[J]. Guangzhou Medical Journal, 2024, 55(11): 1246-1254.

参考文献

[1] KOBAYASHI T,SIEGMUND B,LE BERRE C,et al.Ulcerative colitis[J].Nature Reviews Disease Primers,2020,6(1):74.
[2] SAEZ A,HERRERO-FERNANDEZ B,GOMEZ-BRIS R,et al.Pathophysiology of Inflammatory Bowel Disease:Innate Immune System[J].International Journal of Molecular Sciences,2023,24(2):1526.
[3] MONTAIGNE D,BUTRUILLE L,STAELS B.PPAR control of metabolism and cardiovascular functions[J].Nature Reviews Cardiology,2021,18(12):809-823.
[4] CAIONI G,VISCIDO A,D’ANGELO M,et al.Inflammatory Bowel Disease:New Insights into the Interplay between Environmental Factors and PPARγ[J].International Journal of Molecular Sciences,2021,22(3):985.
[5] NG S C,SHI H Y,HAMIDI N,et al.Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century:A systematic review of population-based studies[J].The Lancet,2017,390(10114):2769-2778.
[6] BUIE M J,QUAN J,WINDSOR J W,et al.Global Hospitalization Trends for Crohn’s Disease and Ulcerative Colitis in the 21st Century:A Systematic Review With Temporal Analyses[J].Clinical Gastroenterology and Hepatology,2023,21(9):2211-2221.
[7] AGRAWAL M,ALLIN K H,PETRALIA F,et al.Multiomics to elucidate inflammatory bowel disease risk factors and pathways[J].Nature Reviews Gastroenterology & Hepatology,2022,19(6):399-409.
[8] SHAN Y,LEE M,CHANG E B.The gut microbiome and inflammatory bowel diseases[J].Annual Review of Medicine,2022,73:455-468.
[9] OHKUSA T.Induction of experimental ulcerative colitis by Fusobacterium varium isolated from colonic mucosa of patients with ulcerative colitis[J].Gut,2003,52(1):79-83.
[10] SCHAUBECK M,CLAVEL T,CALASAN J,et al.Dysbiotic gut microbiota causes transmissible Crohn’s disease-like ileitis independent of failure in antimicrobial defence[J].Gut,2016,65(2):225-237.
[11] YANG Y,ZHENG X,WANG Y,et al.Human fecal microbiota transplantation reduces the susceptibility to dextran sulfate sodium-induced germ-free mouse colitis[J].Frontiers in Immunology,2022,13:836542.
[12] SCHIRMER M,FRANZOSA E A,LLOYD-PRICE J,et al.Dynamics of metatranscription in the inflammatory bowel disease gut microbiome[J].Nature Microbiology,2018,3(3):337-346.
[13] LLEAL M,SARRABAYROUSE G,WILLAMIL J,et al.A single faecal microbiota transplantation modulates the microbiome and improves clinical manifestations in a rat model of colitis[J].EBioMedicine,2019,48:630-641.
[14] FEIGE J N,GELMAN L,MICHALIK L,et al.From molecular action to physiological outputs:Peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions[J].Progress in Lipid Research,2006,45(2):120-159.
[15] DUBOIS V,EECKHOUTE J,LEFEBVRE P,et al.Distinct but complementary contributions of PPAR isotypes to energy homeostasis[J].Journal of Clinical Investigation,2017,127(4):1202-1214.
[16] HAN L,SHEN W J,BITTNER S,et al.PPARs:Regulators of Metabolism and As Therapeutic Targets in Cardiovascular disease.Part I:PPAR-α[J].Future Cardiology,2017,13(3):259-278.
[17] MANSÉN A,GUARDIOLA-DIAZ H,RAFTER J,et al.Expression of the peroxisome proliferator-activated receptor(PPAR)in the mouse colonic mucosa[J].Biochemical and Biophysical Research Communications,1996,222(3):844-851.
[18] CHEN H,TAN H,WAN J,et al.PPAR-γ signaling in nonalcoholic fatty liver disease:Pathogenesis and therapeutic targets[J].Pharmacology & Therapeutics,2023,245:108391.
[19] WU L,LI J,FENG J,et al.Crosstalk between PPARs and gut microbiota in NAFLD[J].Biomedicine & Pharmacotherapy,2021,136:111255.
[20] DELERIVE P,DE BOSSCHER K,BESNARD S,et al.Peroxisome proliferator-activated receptor α negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-κB and AP-1[J].Journal of Biological Chemistry,1999,274(45):32048-32054.
[21] CUZZOCREA S,DI PAOLA R,MAZZON E,et al.Role of endogenous and exogenous ligands for the peroxisome proliferators activated receptors alpha(PPAR-α)in the development of inflammatory bowel disease in mice[J].Laboratory Investigation,2004,84(12):1643-1654.
[22] CUZZOCREA S,BRUSCOLI S,MAZZON E,et al.Peroxisome proliferator-activated receptor-α contributes to the anti-Inflammatory activity of glucocorticoids[J].Molecular Pharmacology,2008,73(2):323-337.
[23] HERRANZ-LÓPEZ M,BARRAJÓN-CATALÁN E,SEGURA-CARRETERO A,et al.Lemon verbena(Lippia citriodora)polyphenols alleviate obesity-related disturbances in hypertrophic adipocytes through AMPK-dependent mechanisms[J].Phytomedicine,2015,22(6):605-614.
[24] YAMAMOTO-FURUSHO J K,JACINTEZ-CAZARES M,FURUZAWA-CARBALLEDA J,et al.Peroxisome proliferator-activated receptors family is involved in the response to treatment and mild clinical course in patients with ulcerative colitis[J].Disease Markers,2014(2014):932530.
[25] MAZZON E,CUZZOCREA S.Absence of functional peroxisome proliferator-activated receptor-alpha enhanced ileum permeability during experimental colitis[J].Shock,2007,28(2):192-201.
[26] GRYGIEL-GÓRNIAK B.Peroxisome proliferator-activated receptors and their ligands:nutritional and clinical implications - a review[J].Nutrition Journal,2014,13:17.
[27] WAGNER N,WAGNER K D.Pharmacological utility of PPAR modulation for angiogenesis in cardiovascular disease[J].International Journal of Molecular Sciences,2023,24(3):2345.
[28] TORAL M,GÓMEZ-GUZMÁN M,JIMÉNEZ R,et al.Chronic peroxisome proliferator-activated receptorβ/δ agonist GW0742 prevents hypertension,vascular inflammatory and oxidative status,and endothelial dysfunction in diet-induced obesity[J].Journal of Hypertension,2015,33(9):1831-1844.
[29] SHAN W,NICOL C J,ITO S,et al.Peroxisome proliferator-activated receptor-β/δ protects against chemically induced liver toxicity in mice[J].Hepatology,2008,47(1):225-235.
[30] BOUGUEN G,LANGLOIS A,DJOUINA M,et al.Intestinal steroidogenesis controls PPARγ expression in the colon and is impaired during ulcerative colitis[J].Gut,2015,64(6):901-910.
[31] BASSAGANYA-RIERA J,REYNOLDS K,MARTINO-CATT S,et al.Activation of PPAR γ and δ by conjugated linoleic acid mediates protection from experimental inflammatory bowel disease[J].Gastroenterology,2004,127(3):777-791.
[32] CHOO J,LEE Y,YAN X JIA,et al.A novel peroxisome proliferator-activated receptor(PPAR)γ agonist 2-Hydroxyethyl 5-chloro-4,5-didehydrojasmonate exerts anti-inflammatory effects in colitis[J].Journal of Biological Chemistry,2015,290(42):25609-25619.
[33] SHEN P,ZHANG Z,HE Y,et al.Magnolol treatment attenuates dextran sulphate sodium-induced murine experimental colitis by regulating inflammation and mucosal damage[J].Life Sciences,2018(196):69-76.
[34] KONG R,LUO H,WANG N,et al.Portulaca extract attenuates development of dextran sulfate sodium induced colitis in mice through activation of PPAR γ[J].PPAR Research,2018(2018):6079101.
[35] NAKAJIMA A,WADA K,MIKI H,et al.Endogenous PPARγ mediates anti-inflammatory activity in murine ischemia-reperfusion injury[J].Gastroenterology,2001,120(2):460-469.
[36] LINARD C,GRÉMY O,BENDERITTER M.Reduction of peroxisome proliferation-activated receptor γ expression by γ-Irradiation as a mechanism contributing to inflammatory response in rat colon:Modulation by the 5-Aminosalicylic acid agonist[J].Journal of Pharmacology and Experimental Therapeutics,2008,324(3):911-920.
[37] RAMAKERS J D,VERSTEGE M I,THUIJLS G,et al.The PPARγ agonist rosiglitazone impairs colonic inflammation in mice with experimental colitis[J].Journal of Clinical Immunology,2007,27(3):275-283.
[38] DESREUMAUX P,DUBUQUOY L,NUTTEN S,et al.Attenuation of colon inflammation through activators of the retinoid X receptor(Rxr)/peroxisome proliferator-activated receptor γ(pparγ)heterodimer[J].The Journal of Experimental Medicine,2001,193(7):827-838.
[39] ONUKI M,WATANABE M,ISHIHARA N,et al.A partial agonist for retinoid X receptor mitigates
experimental colitis[J].International Immunology,2019,31(4):251-262.
[40] DING Y,BU X,ZHANG N,et al.Effects of metabolizable energy and crude protein levels on laying performance,egg quality and serum biochemical indices of Fengda-1 layers[J].Animal Nutrition,2016,2(2):93-98.
[41] ARE A,ARONSSON L,WANG S,et al.Enterococcus faecalis from newborn babies regulate endogenous PPARγ activity and IL-10 levels in colonic epithelial cells[J].Proceedings of the National Academy of Sciences,2008,105(6):1943-1948.
[42] KUNDU P,LING T W,KORECKA A,et al.Absence of intestinal PPARγ aggravates acute infectious colitis in mice through a lipocalin-2-dependent pathway[J].PLoS Pathogens,2014,10(1):e1003887.
[43] WAGNERBERGER S,SPRUSS A,KANURI G,et al.Lactobacillus casei Shirota protects from fructose-induced liver steatosis:A mouse model[J].The Journal of Nutritional Biochemistry,2013,24(3):531-538.
[44] ANGELAKIS E,BASTELICA D,BEN AMARA A,et al.An evaluation of the effects of Lactobacillus ingluviei on body weight,the intestinal microbiome and metabolism in mice[J].Microbial Pathogenesis,2012,52(1):61-68.
[45] SUN S S,WANG K,MA K,et al.An insoluble polysaccharide from the sclerotium of Poria cocos improves hyperglycemia,hyperlipidemia and hepatic steatosis in ob/ob mice via modulation of gut microbiota[J].Chinese Journal of Natural Medicines,2019,17(1):3-14.
[46] OH H Y P,VISVALINGAM V,WAHLI W.The PPAR-microbiota-metabolic organ trilogy to fine‐tune physiology[J].The FASEB Journal,2019,33(9):9706-9730.
[47] ZHANG K,MENG M,GAO L,et al.Sodium butyrate improves high-concentrate-diet-induced impairment of ruminal epithelium barrier function in goats[J].Journal of Agricultural and Food Chemistry,2018,66(33):8729-8736.
[48] HONG Y H,NISHIMURA Y,HISHIKAWA D,et al.Acetate and propionate short chain fatty acids stimulate adipogenesis via GPCR43[J].Endocrinology,2005,146(12):5092-5099.
[49] ZHANG W,CHENG C,HAN Q,et al.Flos Abelmoschus manihot extract attenuates DSS-induced colitis by regulating gut microbiota and Th17/Treg balance[J].Biomedicine & Pharmacotherapy,2019(117):109162.
[50] BYNDLOSS M X,OLSAN E E,RIVERA-CHÁVEZ F,et al.Microbiota-activated PPAR-γ signaling inhibits dysbiotic Enterobacteriaceae expansion[J].Science,2017,357(6351):570-575.
[51] MANOHARAN I,SURYAWANSHI A,HONG Y,et al.Homeostatic PPARα signaling limits inflammatory responses to commensal microbiota in the intestine[J].The Journal of Immunology,2016,196(11):4739-4749.
[52] ZENEWICZ L A,YIN X,WANG G,et al.IL-22 deficiency alters colonic microbiota to be transmissible and colitogenic[J].The Journal of Immunology,2013,190(10):5306-5312.
[53] SHOU J W,SHAW P C.Berberine activates PPARδ and promotes gut microbiota-derived butyric acid to suppress hepatocellular carcinoma[J].Phytomedicine,2023(115):154842.